Minimizing cardiovascular adverse effects of atypical antipsychotic drugs in patients with schizophrenia

Cardiology Research and Practice

Volumn 2014, Issue , 2014, Pages

  Khasawneh, Fadi T ^a   Shankar, Gollapudi S ^a  

^a WESTERN UNIVERSITY OF HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; CHLORPROMAZINE; HALOPERIDOL; MESORIDAZINE; MESORIDAZINE BESYLATE; NEUROLEPTIC AGENT; PIMOZIDE; QUETIAPINE; RISPERIDONE; THIORIDAZINE; ZIPRASIDONE;

BLOOD PRESSURE FLUCTUATION; BLOOD PRESSURE MONITORING; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DISEASE ASSOCIATION; DRUG SAFETY; HEART ARRHYTHMIA; HUMAN; HYPERTENSION; HYPOTENSION; MYOCARDITIS; ORTHOSTATIC HYPOTENSION; PATIENT CARE; PRIORITY JOURNAL; QT PROLONGATION; REVIEW; RISK ASSESSMENT; SCHIZOPHRENIA; SEX RATIO; SUDDEN CARDIAC DEATH; TACHYCARDIA; TORSADE DES POINTES;

EID: 84894748138     PISSN: None     EISSN: 20900597     Source Type: Journal    
DOI: 10.1155/2014/273060     Document Type: Review

References (26)

1. Buckley N. A., Sanders P., Cardiovascular adverse effects of antipsychotic drugs. Drug Safety 2000 23 3 215 228 2-s2.0-0033811846
2. Enger C., Weatherby L., Reynolds R. F., Glasser D. B., Walker A. M., Serious cardiovascular events and mortality among patients with schizophrenia. Journal of Nervous and Mental Disease 2004 192 1 19 27 2-s2.0-0346502779 10.1097/01.nmd.0000105996.62105.07
3. Feinstein R. E., Cardiovascular effects of novel antipsychotic medications. Heart Disease 2002 4 3 184 190 2-s2.0-0036087581
4. Zimmet P., Epidemiology of diabetes mellitus and associated cardiovascular risk factors: focus on human immunodeficiency virus and psychiatric disorders. The American Journal of Medicine 2005 118 supplement 2 3S 8S 2-s2.0-19444377320
5. Nihalani N., Schwartz T. L., Siddiqui U. A., Megna J. L., Weight gain, obesity, and psychotropic prescribing. Journal of Obesity 2011 2011 9 893629 10.1155/2011/893629
6. Henderson D. C., Cagliero E., Gray C., Nasrallah R. A., Hayden D. L., Schoenfeld D. A., Goff D. C., Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: a five-year naturalistic study. American Journal of Psychiatry 2000 157 6 975 981 2-s2.0-0034042934 10.1176/appi.ajp.157.6.975
7. Parks J., Nicol G., Newcomer J., Improving metabolic screening for patients on antipsychotic therapy. Medscape Education Psychiatry & Mental Health 2011
8. Chaggar P. S., Shaw S. M., Williams S. G., Effect of antipsychotic medications on glucose and lipid levels. Journal of Clinical Pharmacology 2010 51 5 631 638
9. Bushe C. J., Taylor M., Haukka J., Mortality in schizophrenia: a measurable clinical endpoint. Journal of Psychopharmacology 2010 24 4, supplement 17 25 10.1177/1359786810382468
10. Grasso B. C., Rothschild J. M., Genest R., Bates D. W., What do we know about medication errors in inpatient psychiatry? Joint Commission Journal on Quality and Safety 2003 29 8 391 400 2-s2.0-0142259246
11. Johnell K., Fastbom J., Rosén M., Leimanis A., Inappropriate drug use in the elderly: a nationwide register-based study. Annals of Pharmacotherapy 2007 41 7-8 1243 1248 2-s2.0-34547151584 10.1345/aph.1K154
12. Cipolle R. J., Strand L. M., Morley P. C., Pharmaceutical Care Practice 1998 New York, NY, USA McGraw-Hill
13. Schatz I. J., Bannister R., Freeman R. L., Goetz C. G., Jankovic J., Kaufmann H. C., Koller W. C., Low P. A., Mathias C. J., Polinsky R. J., Quinn N. P., Robertson D., Streeten D. H. P., Consensus statement on the definition of orthostatic hypotension, pure autonomic failure, and multiple system atrophy. Journal of the Neurological Sciences 1996 144 1-2 218 219 2-s2.0-0030464476 10.1016/S0022-510X(96)00206-7
14. Montastruc J. L., Laborie I., Bagheri H., Senard J. M., Drug-induced orthostatic hypotension. A five-year experience in a regional pharmacovigilance centre in France. Clinical Drug Investigation 1997 14 1 61 65 2-s2.0-0030854661
15. Irvin D. J., White M., The importance of accurately assessing orthostatic hypotension. Geriatric Nursing 2004 25 2 99 101 2-s2.0-2442526882 10.1016/j.gerinurse.2003.10.022
16. Justo D., Prokhorov V., Heller K., Zeltser D., Torsade de pointes induced by psychotropic drugs and the prevalence of its risk factors. Acta Psychiatrica Scandinavica 2005 111 3 171 176 2-s2.0-14844325740 10.1111/j.1600-0447.2004. 00469.x
17. Reilly J. G., Ayis S. A., Ferrier I. N., Jones S. J., Thomas S. H. L., Thioridazine and sudden unexplained death in psychiatric in-patients. British Journal of Psychiatry 2002 180 515 522 2-s2.0-0036263960 10.1192/bjp.180.6.515
18. Harrigan E. P., Miceli J. J., Anziano R., Watsky E., Reeves K. R., Cutler N. R., Sramek J., Shiovitz T., Middle M., A randomized evaluation of the effects of six antipsychotic agents on QTc, in the absence and presence of metabolic inhibition. Journal of Clinical Psychopharmacology 2004 24 1 62 69 2-s2.0-1642579574 10.1097/01.jcp.0000104913.75206.62
19. Glassman A. H., Bigger J. T., Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death. American Journal of Psychiatry 2001 158 11 1774 1782 2-s2.0-0035150202 10.1176/appi.ajp.158.11.1774
20. Manini A. F., Raspberry D., Hoffman R. S., Nelson L. S., QT prolongation and torsades de pointes following overdose of ziprasidone and amantadine. Journal of Medical Toxicology 2007 3 4 178 181 2-s2.0-38749093396
21. Heinrich T. W., Biblo L. A., Schneider J., Torsades de pointes associated with ziprasidone. Psychosomatics 2006 47 3 264 268 2-s2.0-33745936653 10.1176/appi.psy.47.3.264
22. Ray W. A., Meredith S., Thapa P. B., Meador K. G., Hall K., Murray K. T., Antipsychotics and the risk of sudden cardiac death. Archives of General Psychiatry 2001 58 12 1161 1167 2-s2.0-0035199932
23. Marti V., Sudden cardiac death due to risperidone therapy in a patient with possible hypertrophic cardiomyopathy. Annals of Pharmacotherapy 2005 39 5 973 2-s2.0-17644367857 10.1345/aph.1E539
24. Jindal R., MacKenzie E. M., Baker G. B., Yeragani V. K., Cardiac risk and schizophrenia. Journal of Psychiatry and Neuroscience 2005 30 6 393 395 2-s2.0-29144457999
25. Haas S. J., Hill R., Krum H., Liew D., Tonkin A., Demos L., Stephan K., McNeil J., Clozapine-associated myocarditis: a review of 116 cases of suspected myocarditis associated with the use of clozapine in Australia during 1993-2003. Drug Safety 2007 30 1 47 57 2-s2.0-33846074353
26. Kilian J. G., Kerr K., Lawrence C., Celermajer D. S., Myocarditis and cardiomyopathy associated with clozapine. The Lancet 1999 354 9193 1841 1845 2-s2.0-0033610722 10.1016/S0140-6736(99)10385-4